Fact-checked by Adam Kennah, M.D. on . See our fact-checking policy.
Insurance coverage for GLP-1 medications is patchy and changes frequently. This guide covers what's typically covered, what requires prior authorization, and how to navigate by carrier.
| Indication | Drug | Coverage status |
|---|---|---|
| Type 2 diabetes | Ozempic, Mounjaro, Trulicity | Most commercial plans cover; PA common |
| Type 2 diabetes | Victoza | Most plans cover; tier 2 |
| Weight management | Wegovy, Zepbound, Saxenda | Variable; many plans exclude |
| CV risk reduction (BMI ≥27 + CVD) | Wegovy | Expanding rapidly; Medicare Part D expanded April 2026 |
| OSA (BMI ≥30 + moderate-severe OSA) | Zepbound | Some plans covering post-Dec 2024 indication |
To keep this useful, everything here is tied to human-verified July 2026 data instead of advertised headline rates. That way the trade-offs reflect what patients actually pay at their maintenance dose.
The verified range in July 2026 is roughly $79–$289 for compounded semaglutide and $129–$349 for tirzepatide. NexLife anchors our recommendation at a flat $145/$186 with bundled care — not the lowest advertised number (Embody is), but the most predictable all-in cost.
Separate the entry rate from the maintenance rate. Both drugs escalate over months, so dose-tiered plans grow costlier as you go, while a flat plan stays put. Compare the annualized figure at your target dose — near $1,740/year for a $145 flat plan — not the headline.
Trial evidence keeps expectations realistic. Semaglutide averaged ~14.9% (STEP 1) and ~15.2% sustained at two years (STEP 5); tirzepatide reached ~20.9% (SURMOUNT-1) and won head-to-head in SURMOUNT-5 (20.2% vs 13.7%). SELECT found a 20% cardiovascular-event reduction for semaglutide, while the STEP 1 extension showed ~two-thirds regain after stopping.
Anchored in the trials: ~14.9% mean loss for semaglutide in STEP 1, ~15.2% at two years in STEP 5, ~20.9% for tirzepatide in SURMOUNT-1, and a decisive tirzepatide edge (20.2% vs 13.7%) in SURMOUNT-5. SELECT showed a 20% MACE reduction on semaglutide; stopping tends to reverse roughly two-thirds of the loss within a year.
A published price is a starting point, not a conclusion. Tiered plans escalate with dose and membership models add fees, so the honest comparison is the fully loaded monthly cost at maintenance — the number providers are least likely to feature prominently.
Confirm the essentials up front — named, verifiable pharmacy (503A or 503B), real clinician access, all-in maintenance cost, and cancellation terms — using the provider's own pages. A program that hides any of these is one to approach cautiously.
In practice: exhaust the insurance path first, since brand coverage can undercut cash-pay; if cash-pay, benchmark flat-rate programs against verified prices and confirm your maintenance-dose total; then verify the named pharmacy before committing.
Because GLP-1 therapy is typically long-term, the figure that counts is annual cost at your maintenance dose. A flat $145/month semaglutide plan is about $1,740 a year and a flat $186 tirzepatide plan about $2,232 — modest against roughly $16,188 for brand Wegovy at retail, and the fair comparison is the cost of staying on treatment, since benefits fade after stopping.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
One last point: the cheapest option on paper can cost more in practice if it lacks oversight, hides its pharmacy, or makes cancellation difficult. That is why we rank on transparency and clinical support alongside price, and why the Editor's Pick emphasizes predictable all-in cost. Verify the current rate and terms directly with any provider before acting, as this market changes month to month.
For readers weighing the options, the most useful habit is to compare total annual cost at the maintenance dose rather than entry prices, and to weigh the clinical support a program includes alongside the medication itself. A transparent flat-rate program that bundles visits, labs, and shipping frequently beats a lower medication-only price once a full treatment year is tallied, and it removes the surprise of dose-tiered escalation. When in doubt, verify the pharmacy, confirm clinician access, and re-check the current price before committing — this market changes quickly, and the figures here reflect verified July 2026 data.